ReviewDrug design, development and therapy2026
Emerging Roles and Possible Therapeutic Applications of Arachidonic Acid Metabolites in Sepsis and Sepsis-Associated Organ Dysfunction.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptional Profiling of the Landes Goose Cecum Following Infection withMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening syndrome characterized by dysregulated immune responses, frequently complicated by multiple organ dysfunction. Despite advances in supportive care, targeted therapies remain lacking, and sepsis remains a considerable global health burden. Increasing evidence indicates that arachidonic acid and its metabolites are critical regulators of inflammation, immune responses, and apoptosis in the pathophysiology of sepsis. Arachidonic acid is metabolized through cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) pathways, generating diverse eicosanoids with distinct effects. Pro-inflammatory mediators such as prostaglandin E
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.